Letters and Public Comments Submitted to Federal Agencies

Letters and Public Comments Submitted to Federal Agencies by Affiliated Faculty

2026

Comments to the Centers for Medicare and Medicaid Services opposing their proposed rules to prohibit gender-affirming care for young people in hospitals and the Medicaid and CHIP programs (Feb 2026)

Comment supporting continuation of the Pregnancy Risk Assessment Monitoring System (PRAMS) data collection (Jan 2026)

2025

Comment in response to an Office of Science and Technology Policy request for information on "Accelerating the American Scientific Enterprise" (Dec 2025)

Comment to the Environmental Protection Agency regarding its proposal to revoke the finding that greenhouse gas emissions endanger human health (Sept 2025)

Comments to the Department of Health & Human Services on the Personal Responsibility and Work Opportunity Reconciliation Act interpretation of "Federal Public Benefit" (Aug 2025)

Letter to White House Office of Science and Technology Policy regarding "Restoring Gold Standard Science" Executive Order (July 2025)

Comment to the Office of Personnel Management regarding its Schedule Policy/Career proposed rule (June 2025)

2024

Comment to the National Institutes of Health regarding its draft public access policy (89 FR 51537)

Comment for the Environmental Protection Agency regarding its draft scientific integrity policy

Letter to Scientific Integrity Officials regarding a Simple Modification to Address Concerning Provision in Scientific Integrity Policies

2023

Comment in response to "Coverage of Over-the-Counter Preventive Services” request for information (RIN 0938–ZB81)

Comment for the National Institutes of Health regarding its draft scientific integrity policy

Comment on "Regulations To Implement the Pregnant Workers Fairness Act" (Docket EEOC-2023-0004; RIN 3046-AB30)

 Comment for the Department of Health and Human Services regarding its draft scientific integrity policy

Comments for “Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee” (Docket No. FDA-2022-N-1959)

Comment on the NIH Plan to Enhance Public Access to the Results of NIH-Supported Research (NOT-OD-23-091)

Letter to the White House Office of Science and Technology Policy regarding A Framework for Scientific Integrity Policies and Practices

Comments on proposed rule "Coverage of Certain Preventive Services Under the Affordable Care Act" (RINs 0938-AU94; 1210-AC13; 1545-BQ35)

2021

Comment in Response to Request for Information To Improve Federal Scientific Integrity Policies (86 FR 34064)

2019

Comments on proposed rule "Nondiscrimination in Health and Health Education Programs and Activities (Section 1557 NPRM)" (HHS-OCR-2019-0007/RIN 0945-AA11)

2018